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Background: Circulating microRNAs (miRNAs) have been found in many body fluids and represent reliable markers
of several physio-pathological disorders, including cancer. In some cases, circulating miRNAs have been evaluated
as markers of the efficacy of anticancer treatment but it is not yet clear if miRNAs are actively released by tumor
cells or derive from dead tumor cells.
Results: We showed that a set of prostate cancer secretory miRNAs (PCS-miRNAs) were spontaneously released in
the growth medium by DU-145 prostate cancer cells and that the release was greater after treatment with the
cytotoxic drug fludarabine. We also found that the miRNAs were associated with exosomes, implying an active
mechanism of miRNA release. It should be noted that in fludarabine treated cells the release of miR-485-3p, as well
as its association with exosomes, was reduced suggesting that miR-485-3p was retained by surviving cells.
Monitoring the intracellular level of miR-485-3p in these cells, we found that miR-485-3p was stably up regulated
for several days after treatment. As a possible mechanism we suggest that fludarabine selected cells that harbor
high levels of miR-485-3p, which in turn regulates the transcriptional repressor nuclear factor-Y triggering the
transcription of topoisomerase IIα, multidrug resistance gene 1 and cyclin B2 pro-survival genes.
Conclusions: Cytotoxic treatment of DU-145 cells enhanced the release of PCS-miRNAs with the exception of miR-
485-3p which was retained by surviving cells. We speculate that the retention of miR-485-3p was a side effect of
fludarabine treatment in that the high intracellular level of miR-485-3p plays a role in the sensitivity to fludarabine.
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MicroRNAs (miRNAs) are released in the body fluids
and due to their abundance and stability they can be
easily detected and/or monitored over long periods
[1-5]. If either physiological or pathological disorders
affect the human body, the miRNA signature of body
fluids is shifted, making them useful diagnostic/prognos-
tic markers for a given disorder [6-11]. Prostate cancer
patients have been found to have specific miRNAs (pros-
tate cancer secretory miRNAs, PCS-miRNAs) overrepre-
sented in their plasma/serum, these are currently
considered potential markers for the disease [3,12-17].
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reproduction in any medium, provided the oras markers of the efficacy of anticancer treatment [17],
but it is not yet clear if miRNAs are actively released by
tumor cells or derive from dead tumor cells. We
approached this aspect using cancer cell lines, as they
offer the possibility to determine both intracellular and
extracellular miRNAs, thus allowing investigation of
whether cancer cells treated with a cytotoxic drug re-
lease miRNAs in the growth medium like untreated
cells.
Here we report that DU-145 prostate cancer cells re-
lease a set of PCS-miRNAs and that after a treatment
with fludarabine, a drug which preferentially blocks the
progression of cells toward S phase and later induces cell
death [18], the release of PCS-miRNAs was enhanced
with the exception of miR-485-3p which was retained by
surviving cells. We speculate that the reduced release of
miR-485-3p was a side effect of fludarabine treatmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mining the sensitivity of DU-145 cells to the drug.
Results
PCS-miRNAs are released into the growth medium by the
DU-145 tumor cells.
To build a reliable in vitro model to study miRNA re-
lease, we verified whether the DU-145 prostate cancer
cell line spontaneously releases miRNAs into the growth
medium. To address this question we considered 5
prostate cancer secretory miRNAs (PCS-miRNAs)
and 5 secretory miRNAs (S-miRNAs) representative re-















































































































Figure 1 PCS- and S-miRNAs levels in the growth medium of DU-145
miRNAs (black bars) and S-miRNAs (white bars) in DU-145 cells in comparis
subtracting the expression value of PNT1-A cells from that of DU-145 cells
intracellular (Intra) to extracellular (Extra) levels of PCS- and S-miRNAs, expre
left quarter: Intra down regulated, Extra up regulated; Upper right quarter: In
regulated, Extra down regulated; Lower right quarter: Intra up regulated, Ext
independent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired t-test).overrepresented in the plasma/serum of patients with
prostate cancer [3,14,16]. We found that in comparison
to the immortalized prostate epithelial cell line PNT1-A,
all PCS-miRNAs (with the exceptions of miR-21) were
more abundant in the growth medium of DU-145 cells,
unlike S-miRNAs (Figure 1A). These data indicate that
DU-145 cells were able to release the same miRNAs that
are overrepresented in the plasma of prostate tumor
patients.
We then asked if the release of miRNAs was
influenced by their endogenous expression levels. We
quantified the intracellular levels of our panel of

























































































cells. Extracellular (A) and intracellular (B) expression levels of PCS-
on to PNT1-A cells. The fold change of each miRNA was calculated by
and then normalizing with the value of PNT1-A cells. C, dot plot of
ssed as fold changes in DU-145 in comparison to PNT1A cells. Upper
tra up regulated, Extra up regulated; Lower left quarter: Intra down
ra down regulated. All data were shown as S.D. from three
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(Figure 1B). The dot plot of the intracellular versus the
extracellular levels showed a positive correlation for
many PCS-miRNAs whereas this correlation was not ob-
served for S-miRNAs (Figure 1C) suggesting a positive
relationship between the intracellular and the extracellu-








































































Figure 2 Effects of fludarabine on DU-145 cells. A, relative cell prolifera
10 μg/ml) of fludarabine. Cell cycle analysis (B), apoptosis (C) and plating e
fludarabine. Dot plot of intracellular (Intra) to extracellular (Extra) levels of P
to untreated DU-145 cells with 10 μg/ml (E) or 1 μg/ml (F) of fludarabine.
quarter: Intra up regulated, Extra up regulated; Lower left quarter: Intra dow
regulated, Extra down regulated. All data were shown as S.D. from three in
t-test).The release of PCS-miRNAs is enhanced by a cytotoxic
treatment
We investigated the release of miRNAs after the expos-
ure of DU-145 cells to a cytotoxic drug. We selected
fludarabine, a drug which we have already used to in-
duce cytotoxicity in tumor cells, as representative of















































































tion of DU-145 cells exposed for 48 h to increasing concentrations (0-
fficiency (D) of DU-145 cells exposed for 48 h to 10 μg/ml of
CS- and S-miRNAs, expressed as fold changes in treated in comparison
Upper left quarter: Intra down regulated, Extra up regulated; Upper right
n regulated, Extra down regulated; Lower right quarter: Intra up
dependent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired
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from the dose-response curve we selected 10 μg/ml
fludarabine as at this concentration cell proliferation was
inhibited (Figure 2A). The cell-cycle analysis of DU-145
treated cells showed a blockage of cells in S and a strong
depletion of G2 cells (Figure 2B). A slight but significant
increase of apoptotic cells was also found (Figure 2C).
The finding that after fludarabine treatment a substantial
fraction (25%) of DU-145 cells was able to form colonies
(Figure 2D) suggested that there were many surviving
cells. Therefore, at the end of 48 h treatment we col-
lected both attached cells and growth medium and mea-
sured the levels of our sets of miRNAs and calculated
fold change of expression in treated versus untreated
samples. The dot plot of the intracellular versus the
extracellular fold changes showed that, while S-miRNAs
had little variations after fludarabine treatment, almost
all PCS-miRNAs were up regulated and released into
the growth medium with the exception of miR-485-3p,
which was less released by tumor cells despite its intra-
cellular up regulation (Figure 2E). Interestingly, decreas-
ing the concentration of fludarabine to 1 μg/ml, a
concentration which reduced cell proliferation by 50%
(Figure 2A), miR-485-3p was still retained (Figure 2F).
In order to define if miR-485-3p retention was com-
mon in prostate cancer cell lines, we extended the ana-
lysis of retention/release of miR-485-3p to PC-3, a
prostate cancer androgen resistant cell line, and 22Rv1
and LNCaP, two androgen sensitive prostate cancer cell
lines. Following the treatment with a concentration of
fludarabine able to inhibit cell proliferation, we found
that miR-485 was released in the growth medium of
PC-3, 22Rv1 and LNCaP (Additional file 1: Figure
S1A, B, C respectively), suggesting that the induction
of release/retention is a process dependent on the
genetic background. Then we asked whether the
process was drug specific. We treated DU-145 cells
with taxotere, a drug used for the treatment of pros-
tate cancer. The dot plot of intracellular versus extra-
cellular fold change of miRNAs levels showed that
taxotere did not affected miR-485-3p retention/release
(Additional file 1: Figure S1D) introducing the con-
cept that a signature interaction between drug and
genetic background exists.
Exosomes are involved in the release of PCS-miRNAs
To address if the release of PCS-miRNAs enhanced by
fludarabine occurs through an active mechanism, we
detected their loading on exosomes. We isolated
exosomes from the growth medium of DU-145 cells
treated (EXO-flu+) or untreated (EXO-flu-) with
fludarabine. Once we had verified that the amounts of
EXO-flu+ and EXO-flu- were similar and that exosomes
were functionally active (Additional file 2: Figure S2), wedetermined the fold change of PCS-miRNAs and S-
miRNAs in EXO-flu+ compared to EXO-flu-. We found
that fludarabine favored the association of almost all
PCS-miRNAs and S-miRNAs to EXO-flu+ compared to
EXO-flu- with the exception of miR-485-3p (Figure 3A).
MiR-485-3p was released less by treated cells and less
loaded on EXO-flu+ than on EXO-flu- suggesting that
fludarabine affects the association of miR-485-3p with
exosomes.
To support this hypothesis, DU-145 cells were
transfected with either miR-485-3p or miR-100 and the
expression of miRNAs was measured in the exosomes
released by transfected cells treated (miR-485-3p/EXO-
flu+ or miR-100/EXO-flu+) or untreated (miR-485-3p/
EXO-flu- or miR-100/EXO-flu-) with fludarabine. Firstly,
we observed that the two miRNAs were highly loaded
on exosomes isolated from transfected cells (Figure 3B).
When transfected cells were treated with fludarabine, we
found that miR-485-3p/EXO-flu+ were less loaded with
miR-485-3p than miR-485-3p/EXO-flu- whereas miR-
100/EXO-flu+ were loaded with miR-100 to a similar
extent to miR-100/EXO-flu- (Figure 3C). Since the asso-
ciation of miR-485-3p with exosomes was efficient in
untreated cells but inhibited in fludarabine surviving
cells, the possible explanations are that fludarabine alter
the availability of miR-485-3p for the export or, alterna-
tively, that fludarabine selected cells with a reduced abil-
ity to associate miR-485-3p with exosomes. In both
cases the final result is that surviving cells were those
enriched for miR-485-3p.
To investigate whether cells harboring high levels of
miR-485-3p were induced or selected by fludarabine, we
monitored the expression of miR-485-3p and its indirect
target multidrug resistance gene 1 (MDR1) for 144 h (6
days) in fludarabine surviving cells. At the beginning of
the treatment (t=0) the expression levels of miR-485-3p
and MDR1 were respectively 2.5 and 5 fold higher in
treated than in untreated cells and the high expression
levels were stably maintained to late time points
(Figure 3D). Due to the stable up regulation, it seems
that fludarabine selected cells with a high intracellular
level of miR-485-3p. To clarify this apparent relationship
DU-145 cells were first transfected with an antagomiRNA
specific for miR-485-3p and then treated with fludarabine.
We found that cells depleted of miR-485-3p were more
sensitive to fludarabine (Figure 3E) thus establishing that
miR-485-3p was a modulator of the sensitivity to
fludarabine.
miR-485-3p protects DU-145 cells from the
antiproliferative effects of fludarabine
To investigate the mechanism(s) that mediate(s) the re-
duction of sensitivity to fludarabine, we looked at the











































































































































































































Figure 3 PCS- and S-miRNAs levels in the exosomes isolated from DU-145 cells growth medium. A, fold change of PCS- (black bars) and
S- (white bars) miRNAs levels in exosomes isolated from the growth medium of DU-145 fludarabine treated in comparison to untreated cells. B,
relative miR-485-3p or miR-100 levels in exosomes of DU-145 cells transfected with miR-485-3p and miR-100 respectively versus those of miR-NC
transfected cells. C, relative miR-485-3p or miR-100 levels in exosomes of DU-145 cells transfected with miR-485-3p or miR-100 respectively and
then treated with fludarabine versus those of transfected but untreated cells. D, fold change of the expression levels of MDR1 and miR-485-3p in
DU-145 cells at different time points after fludarabine treatment. E, cell proliferation of DU-145 cells transfected with antagomiRNA-485-3p (d-485-
3p) or antagomiRNA-NC (d-NC) and after having been exposed (+flu) or unexposed (-flu) to fludarabine for 48 h. All data were shown as S.D.
from three independent experiments (*P<0.05, **P<0.01, ***P<0.001, unpaired t-test).
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which is post-transcriptionally inhibited by miR-485-3p
and is a transcriptional repressor of topoisomerase IIα
(Top2α) [20] (Figure 4A). The immunoblot analysisshowed that NF-YB was down regulated in fludarabine-
treated cells (Figure 4B) and accordingly Top2α was up
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Figure 4 Molecular characterization of fludarabine surviving cells. A, schematic representation of the miR-485-3p/NF-YB/Top2α axis in cells
surviving the treatment of fludarabine. B, western blot analysis and quantification of NF-YB after fludarabine treatment. QRT-PCR analysis (C) and
western blot analysis and quantification (D) of Top2α after fludarabine treatment. E, schematic representation of miR-485-3p/NF-YB-p53/MDR1 or
CCNB2 axis in cells surviving treatment of fludarabine. F, representative immunoblot of p53 levels in cellular lysates of DU-145 cells treated (+) or
untreated (-) with fludarabine (INPUT), in immunoprecipitates (IP) with anti NF-YB and anti-FLAG antibodies. G, relative expression level of CCNB2
and MDR1 in DU-145 cells treated with fludarabine versus untreated cells. All data were shown as S.D. from three independent experiments
(*P<0.05, **P<0.01, ***P<0.001, unpaired t-test).
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and MDR1 [22], have been reported to be repressed by
NF-YB when associated with p53 (Figure 4E) [21]. Co-
immunoprecipitation experiments demonstrated that
NF-YB and p53 interact in DU-145 cells (Figure 4F). In
accordance with this, we observed the down regulationof NF-YB and the up regulation of CCNB2/MDR1 (Fig-
ure 4G) in fludarabine-treated cells. A possible scenario
is that cells harboring high levels of miR-485-3p were
able to proliferate as the down regulation of the tran-
scription factor NF-YB triggered the transcription of
multiple pro-survival genes.
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In this work we used DU-145 prostate cancer cells as an
in vitro model to address whether the release of marker
miRNAs by tumor cells is affected by treatment with a
cytotoxic drug. Firstly, we showed that the prostate cancer
cell line DU-145 spontaneously releases PCS-miRNAs in
higher amounts than S-miRNAs in comparison to PNT1A
cells. Secondly, we report that the released PCS-miRNAs
were up regulated within cells, suggesting that in physio-
logical conditions the release might represent a compensa-
tory mechanism between the endogenous and the
exogenous microenvironments. Thirdly, we show that
fludarabine enhances the release into the growth medium
of PCS-miRNAs but not of S-miRNAs, suggesting that
the release under cytotoxic treatment was a regulated
process. Finally, we report that the release/retention
process is dependent on either the genetic background of
the cells or the cytotoxic drug used.
Several studies have indicated that miRNAs can be ac-
tively secreted by living cells. Even if the secretory mech-
anism of miRNAs remains unclear so far, two different
paths have been suggested: active secretion by a protein-
miRNA complex or via cell-derived membrane vescicles
(MVs) [23]. Among the MVs family we considered
exosomes, small (40-100 nm) MVs of endocytic origin
that contain a great variety of proteins, mRNAs and
miRNAs [24,25]. A growing body of evidence indicates
that exosomal miRNAs can be transferred from a donor
to a recipient cell, mediating intercellular communica-
tion [26-28]. While exosomes are not a new discovery,
recent evidence has indicated a wide range of application
of exosomes research, including disease diagnosis
[29-33] and prognosis [34], drug delivery [35] and more.
We analyzed exosomes isolated from the growth
medium of DU-145 cells either treated or untreated with
fludarabine and found that the exosomes of treated cells
(EXO/flu+) were more heavily loaded than the exosomes
of untreated cells (EXO/flu-) for both PCS-miRNAs and
S-miRNAs. These data seem to indicate that exosomes
are used to export miRNAs from the intracellular to the
extracellular environment and confirm that the release
through exosomes is proportional to the intracellular ex-
pression level of each miRNA.
Intriguingly, miR-485-3p, in spite of its intracellular up
regulation, was released less in the growth medium of
fludarabine treated cells and, in addition, it was less
loaded on EXO/flu+ than on EXO/flu-. The reduced
loading was confirmed by transfecting DU-145 cells with
either miR-485-3p or miR-100. We observed that both
miRNAs were loaded on exosomes, however when
transfected cells were treated with fludarabine, miR-485
-3p but not miR-100 loading was impaired. As miR-485
-3p was associated with exosomes as efficiently as miR-
100 in untreated cells, whereas only miR-485-3p was lessassociated with exosomes in treated cells, the hypothesis
was that fludarabine selected cells with a reduced ability
to export miR-485-3p either free or associated with
exosomes.
Indeed, we showed that fludarabine surviving cells
harvested at several days after treatment were stably
overexpressing miR-485-3p suggesting that this miRNA
was involved in survival. To highlight a possible mecha-
nisms through which the high expression levels of miR-
485-3p favored the survival of DU-145 cells treated with
fludarabine, we looked at the molecular targets of miR-
485-3p. It has been reported that miR-485-3p post-
transcriptionally regulates NF-YB, a direct transcriptional
repressor of Top2α gene [20] and of MDR1 and CCNB2
genes when associated to p53 [21,22]. We observed that
cells surviving the treatment of fludarabine showed en-
hanced expression of miR-485-3p, down regulation of NF-
YB and the activation of Top2α, MDR1 and CCNB2 genes
suggesting that cells were less sensitive to fludarabine as
they had this pathways activated.
Conclusions
In this paper we demonstrate that prostate cancer
secretory miRNAs were released in the growth medium of
prostate cancer cells either untreated or treated with
fludarabine and that exosomes were involved in the export
of miRNAs from the intra to the extracellular environment.
We also report that miR-485-3p was highly expressed but
poorly released in DU-145 cells surviving the cytotoxic
treatment and that DU-145 cells harboring high expression
level of miR-485-3p were able to survive the treatment
with fludarabine probably because miR-485-3p mediated
the activation of a network of prosurvival genes.
Materials and methods
Reagents
miRNeasy mini kit, QuantiTect Reverse Trascription Kit,
QuantiTect SYBER Green PCR kit, miScript Reverse Tran-
scription Kit, miScript SYBR Green PCR Kit, Polyfect Trans-
fection Reagent (QIAGEN, Hilden, Germany); RPMI 1640
medium, Ham’s nutrient mixture F-12 (EuroClone); crystal
violet, anti α-tubulin, anti FLAG M2, Hoechst 33258 (Sigma-
Aldrich Corporation, Seelze, Germany); ECL, Hybond-C
extra membranes (GE Healthcare, Cleveland, Ohio); anti
Top2α (BD Biosciences, San Jose, California); anti NF-YB
(GeneSpin, Milan, Italy); anti-CD63, HRP-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology, Dallas, Texas);
anti p53 (DakoCytomation, Glostrup, Denmark); TMRE,
DiIC18 (Invitrogen, Life Technologies, Carlsbad, California);
Dynabeads Protein G (Novex, Life Technologies, Carlsbad,
California); fludarabine (Teva, Petah Tikva, Israel); taxotere
(Taxotere, Sanofi Aventis, Milan, Italy); single stranded cel-
miR-39, miR-485-3p, miR-100, miR-NC, d-485-3p, d-NC
(GenePharma, Shanghai, China).
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DU-145, PNT1A, 22Rv1 and LNCaP cell lines were grown
in RPMI 1640 medium. PC-3 were grown in Ham’s F-12.
In all media 10% FBS, 1% penicillin/streptomycin (2 mM)
and 1% L-glutammine (2 mM) were added to all media.
Cells were incubated at 37°C in a humidified atmosphere
containing 6% CO2. For fludarabine treatment, cells were
grown for 24 h and treated with 10 μg/ml for 48 h (DU-
145 and PC-3 cells) or 30 μg/ml for 48 h (22Rv1 and
LNCaP). For taxotere treatment, cells were grown for 24 h
and treated with 10nM taxotere for 48 h.
Transfection of mature miRNAs and antagomiRNAs
Approximately 2×105 cells were seeded in each well of a
6-well plate. After 24 h, cells were transfected with
Polyfect Transfection Reagent according to the manufac-
turer instructions. We transfected the following oligonu-
cleotides: either miR-485-3p (5′-GUCAUACACGGCU
CUCCUCUCU-3′; 5′-AGAGAGGAGAGCCGUGUA U
UUC-3′) or miR-100 (5′-AACCCGUAGAUCCGAAC
UUGU-3′; 5′-CAAGUUCGGAUCUACG GAUUAU-3′);
antagomiRNA-485-3p (d-485-3p) (5′-AGAGAGGAGA
GCCGUGUAUGACT-3′). As control we used either miR-
NC (5′-UUCUCCGAACGUGUCACGUTT-3′; 5′-ACGU
GAC ACGUUCGGAGAATT-3′) or antagomiRNA-NC
(d-NC) (5 –CAGUACUUUUGUGUAGUAC AA-3′). After
6H hours from transfection, we added fresh growth
medium and treated cells with fludarabine at 10 μg/ml.
Extraction of RNA from the growth medium
Total RNA was extracted from 200 μl growth medium
using the miRNEasy mini kit following the manufacturer
recommendations (Purification of RNA from serum or
plasma, Qiagen supplementary Protocol). According to
the protocol, 5 μM cel-miR-39 (5′ -UCACCGGG
UGUAAAUCAGCUUG- 3′) was added after the Qiazol
step of the extraction protocol.
Cell proliferation
Cell proliferation was measured as follows: 2×105 cells
per 6 well plate were seeded and after the treatment with
fludarabine or treatment plus transfection, cells were
fixed in 2% paraformaldehyde in PBS and subsequently
stained with 0.1 % crystal violet dissolved in 20% metha-
nol and let dry at room temperature. Cells were then
lysed with 10% acetic acid and the optical density (OD
590 nm) of the solution, detected with Plate Reader ap-
paratus (SpectraCount, Packard), was used to measure
cell proliferation.
Cell cycle
At specified time points cells were stained with
propidium iodide and the cell cycle analyzed using a
FACScalibur cytofluorimeter (BD Biosciences, San Jose,California). The percentage of cells in each phase was
determined and the fold change of treated in compari-
son to untreated cells was calculated.
Apoptosis assay
Apoptosis was detected using the cationic dye TMRE, a
fluorescent probe that measures the loss of mitochondrial
membrane potential associated with apoptosis [36].
Briefly, DU-145 treated or untreated cells were harvested,
incubated with 100 nM TMRE for 40 min at 37°C in the
dark and then analyzed by flow cytometry. The percentage
of apoptotic cells was measured from the SSC density
plots obtained.
Plating efficiency
Cells exposed to fludarabine for 48 h were collected,
counted and seeded at cell density of 200 cells/100 mm
diameter culture dish to allow colony formation. After
10-12 days colonies were detected by staining dishes
with 0.1 % crystal violet. Plating efficiency (no colonies/
no seeded cells) of treated cells was normalized to that
of the untreated cells.
Quantification of miRNAs and mRNAs with Real-time PCR
Total RNA was extracted from 1×106 cells using the
miRNeasy mini kit following the manufacturer’s recom-
mendations. To quantify multidrug resistance gene 1
(MDR1), Top2α and cyclin B2 (CCNB2), 1μg of total
RNA was reverse transcribed using the QuantiTect Re-
verse Trascription Kit. Real-time PCR (qRT-PCR) was
carried out with Rotor-Gene Q 2-Plex (Qiagen, Hilden,
Germany) using the QuantiTect SYBR Green PCR kit.
To quantify miRNAs, 1 μg of total RNA or 5-10 μl of
RNA extracted from 200 μl growth medium were
retrotranscribed with miScript Reverse Transcription Kit
and qRT-PCR was carried out using the miScript SYBR
Green PCR Kit. All reactions were performed in tripli-
cate. Relative quantification of mRNAs and miRNAs ex-
pression was calculated with the fit point method.
Transcript values were normalized to those obtained
from the amplification of the internal control (glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) for
mRNAs, U6 for intracellular miRNA and cel-miR-39 for
extracellular miRNAs). The oligonucleotide sequences
are reported in (Additional file 3: Figure S3).
Western blot analysis
Equivalent amounts of proteins were resolved on SDS-
PAGE gels at different acrylamide percentages and trans-
ferred to Hybond-C extra membranes by electroblotting.
The resulting blots were blocked with 5% nonfat dry milk
or BSA solution in TBST. Anti α-tubulin (1:20000), anti
CD63 (1:500), anti Top2α (1:1000), anti NF-YB (1:1000)
and anti p53 (1:5000) primary antibodies were used.
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were revealed after incubation with the recommended
secondary antibody coupled to peroxidase using ECL.
Scanned images were quantified using OptiQuant soft-
ware and normalized to α-tubulin.
Coimmunoprecipitation assay
1 mg of protein extracted from either DU-145 or DU-145
fludarabine treated cells were used in a coimmu-
noprecipitation assay. Sample were immunoprecipitated
with 4 μg of either anti NF-YB or anti FLAG (as a control
for aspecific immunoprecipitation) using Dynabeads Pro-
tein G following the manufacturers recommendations and
separated on SDS-PAGE gels as described in the section
Western Blot analysis.
Isolation of exosomes
Exosomes were isolated according to Wang [37], with
some modifications. Briefly, growth media were
centrifuged at 2,000 × g for 30 min to remove cells and
debris. The supernatant was transferred to a new tube
and centrifuged at 10,000 × g for 45 min to further re-
move cells and debris. The supernatant was filtered
through a 0.2 μm filter to remove particles larger than
200 nm (mainly microvesicles). Exosomes were then
pelleted from microvesicles-depleted supernatant by
centrifuging at 100,000 × g for 2 h. Exosomes were
washed with PBS and resuspended in 50 μl PBS.
Additional files
Additional file 1: Figure S1. To investigate whether the retention/
release of miR-485-3p was cell line dependent, we treated the androgen
independent PC-3 (A), and two androgen dependent 22Rv1 (B) and
LNCaP (C) prostate cancer cell lines with fludarabine. After 48 h treatment
with a concentration of fludarabine able to inhibit cell proliferation and
to leave surviving cells (PC3=10μg/ml; 22Rv1 and LNCaP=30μg/ml),
growth media and cells were collected and the levels of intracellular and
extracellular PCS- and S-miRNAs were evaluated. The dot plot of
intracellular (Intra) and extracellular (Extra) miRNAs levels, expressed as
fold changes in treated in comparison to untreated cells, showed that
miR-485-3p was up regulated and released by PC3 (A) and 22Rv1 (B) and
only release by LNCaP (C) cells suggesting that the retention/release was
affected by the genetic background. We also tested whether the
retention/release was strictly dependent on the univocal interaction
between a given drug and genetic background. We treated DU-145 cells
with 10nM taxotere, a specific drug for the treatment of prostate cancer,
and after 48 h treatment growth medium and cells were collected and
analysed as described above. We observed that the retention/release of
miR-485-3p was unaffected (D) suggesting that the release of miR-485-3p
was drug dependent. Upper left quarter: Intra down regulated, Extra up
regulated; Upper right quarter: Intra up regulated, Extra up regulated;
Lower left quarter: Intra down regulated, Extra down regulated; Lower
right quarter: Intra up regulated, Extra down regulated.
Additional file 2: Figure S2. Upper panel, western blot analysis of CD63
(a general exosomal marker) in exosomes isolated from treated or
untreated DU-145 cells. The same volume of proteins extracted from
exosomes isolated from treated and untreated cells were loaded. The
Ponceau S staining was used as loading control. Lower panel, to be
confident that the exosomes isolation procedure was able to isolateintact exosomes, we tested their functionality. Exosomes of DU-145 cells
were labelled with DiIC18 according to Zhang [38], with some
modifications. Briefly, DU-145 cells were labelled overnight with the
lipophilic fluorescent tracer DiIC18. The culture medium was collected
the following day and labelled exosomes were purified by the
ultracentrifugation method (as described in Materials and Methods
section). Purified exosomes were resuspended in RPMI 1640 medium
supplemented with 10% FCS and added to the medium of exponentially
growing DU-145 cells. Exosome uptake was monitored at 6, 12 and 24 h
after their administration. At these time points cells were washed with
PBS, fixed with PFA 2%, labelled with Hoechst stain and observed under
fluorescence microscopy. A progressive increase of labelled cells was
observed (from 6 h to 24 h). After 24 h almost all cells were labelled
(right panel). White arrows indicate exosomes fused with the recipient
cell membranes.
Additional file 3: Figure S3. Oligonucleotides sequence.
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